Pfizer’s $5.4B GBT Bet Disappoints Again as Sickle Cell Therapy Fails in Phase III
Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain episodes in patients with sickle cell disease over the 48-week treatment period.Read more:
biospace.comBiotechnology